Your email has been added to our waiting list and we will send an invite to you as soon as possible. Thank you for your patience.
In the meantime, if you happen to run a blog, our newly launched Blog Enhancement Suite can utilize the immense power of community to help you get more audience, engagement, content, and revenue with your own embeddable community! It will breathe new life into your blog and can automate many of the tedious tasks that come with the territory, so you can focus more on what matters most... writing.
Help spread the word about Snapzu:
Let others know about Snapzu by tweeting about us. We appreciate every mention!
Two decades of Alzheimer’s research was based on deliberate fraud by 2 scientists
Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, and the trial results were eagerly awaited as one of the most promising treatments in years. It did not work.